...
首页> 外文期刊>Arteriosclerosis, thrombosis, and vascular biology >Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity.
【24h】

Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity.

机译:抑制血小板与胶原蛋白的相互作用:在肥胖症中,胰岛素的体内作用被胰岛素抵抗所废除。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Insulin resistance is associated with an increased risk of atherothrombotic vascular disease, but the mechanisms are poorly understood. We determined how insulin in vivo regulates platelet activation in nonobese and obese subjects by using methods mimicking thrombus formation. Twelve nonobese (aged 42+/-2 years, body mass index 24.0+/-0.4 kg/m(2)) and 14 obese (aged 43+/-1 years, body mass index 37.2+/-1.5 kg/m(2)) subjects were studied under euglycemic hyperinsulinemic (3-hour insulin infusion of 1 mU. kg(-1). min(-1)) conditions. Before and at the end of hyperinsulinemia, the following were determined: (1) platelet-related early hemostasis (shear rate of approximately 4000 s(-1)) by platelet function analysis; (2) platelet deposition to collagen during whole-blood perfusion (shear rate of 1600 s(-1)); (3) aggregation responses to collagen, thrombin receptor-activating peptide, ADP, and epinephrine; and (4) platelet cGMP concentrations. Insulin action on glucose metabolism was 69% lower in the obese subjects (1.6+/-0.2 mg. kg(-1). min(-1)) than in the nonobese subjects (5.4+/-0.4 mg. kg(-1). min(-1), P<0.0001). The in vivo insulin infusion inhibited platelet deposition to collagen from 4.3+/-0.6x10(6) to 3.5+/-0.4x10(6) per square centimeter in the nonobese subjects (P<0.05) but failed to do so in the obese subjects (5.2+/-0.8x10(6) versus 5.5+/-0.7x10(6) per square centimeter, P=NS; P<0.01 versus nonobese subjects). Epinephrine- and ADP-primed closure times by platelet function analysis were prolonged by insulin in the nonobese but not the obese subjects (P<0.05 for between-group difference). In the nonobese subjects, insulin decreased aggregation to all agonists and significantly increased platelet cGMP concentrations (2.5+/-0.3 versus 3.2+/-0.5 pmol/10(9) for before versus after insulin, respectively; P<0.01). In the obese subjects, insulin did not alter collagen-induced aggregation or cGMP concentrations (1.9+/-0.2 versus 1.8+/-0.1 pmol/10(9) for before versus the end of in vivo hyperinsulinemia, respectively; P=NS). These data demonstrate that normal in vivo insulin action inhibits platelet interaction with collagen under conditions mimicking thrombus formation and reduces aggregation to several agonists. These platelet-inhibitory actions of insulin are blunted or absent in obese subjects and could provide 1 mechanism linking insulin resistance to atherothrombotic disease.
机译:胰岛素抵抗与动脉粥样硬化性血栓性血管疾病的风险增加相关,但其机制了解甚少。我们通过模拟血栓形成的方法,确定了胰岛素在体内如何调节非肥胖和肥胖受试者的血小板活化。十二个非肥胖者(年龄42 +/- 2岁,体重指数24.0 +/- 0.4 kg / m(2))和14个肥胖者(年龄43 +/- 1岁,体重指数37.2 +/- 1.5 kg / m( 2))在正常血糖高胰岛素(3小时胰岛素输注1 mU。kg(-1)。min(-1))条件下进行研究。在高胰岛素血症之前和结束时,确定以下内容:(1)通过血小板功能分析确定与血小板相关的早期止血(剪切速率约为4000 s(-1)); (2)在全血灌注过程中血小板沉积到胶原蛋白上(剪切速率为1600 s(-1)); (3)对胶原蛋白,凝血酶受体激活肽,ADP和肾上腺素的聚集反应; (4)血小板cGMP浓度。肥胖受试者(1.6 +/- 0.2 mg。kg(-1)。min(-1))中胰岛素对葡萄糖代谢的作用比非肥胖受试者(5.4 +/- 0.4 mg。kg(-1)低69% ).min(-1),P <0.0001)。在非肥胖受试者中,体内胰岛素输注抑制了血小板沉积到胶原蛋白的沉积,从每平方厘米4.3 +/- 0.6x10(6)到3.5 +/- 0.4x10(6)(P <0.05),但在肥胖者中没有这样做受试者(5.2 +/- 0.8x10(6)对5.5 +/- 0.7x10(6)每平方厘米,P = NS;对非肥胖受试者,P <0.01)。在非肥胖而非肥胖人群中,胰岛素可延长肾上腺素和ADP引发的血小板功能关闭时间,但两组之间差异无统计学意义(P <0.05)。在非肥胖受试者中,胰岛素降低了所有激动剂的聚集,并显着增加了血小板cGMP浓度(胰岛素治疗前后分别为2.5 +/- 0.3与3.2 +/- 0.5 pmol / 10(9); P <0.01)。在肥胖的受试者中,胰岛素没有改变胶原蛋白诱导的聚集或cGMP浓度(分别为体内高胰岛素血症发生之前和结束时的1.9 +/- 0.2对1.8 +/- 0.1 pmol / 10(9); P = NS) 。这些数据表明,在模仿血栓形成的条件下,正常的体内胰岛素作用抑制了血小板与胶原蛋白的相互作用,并减少了几种激动剂的聚集。在肥胖受试者中,胰岛素的这些血小板抑制作用变钝或不存在,并且可以提供将胰岛素抵抗与动脉粥样硬化性疾病联系起来的一种机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号